|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-10-17
|
|
pubmed:abstractText |
Curative treatment of thyroid cancer is a major issue for patients with end stage renal disease (ESRD) undergoing dialysis because they might not be included in a renal transplant protocol once they have overcome this disease. Since 131I is mostly eliminated by the kidneys, there is concern regarding the toxicity, efficacy and feasibility of 131I-therapy of anuric dialyzed patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1824-4785
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
363-70
|
|
pubmed:meshHeading |
pubmed-meshheading:17043635-Adult,
pubmed-meshheading:17043635-Aged, 80 and over,
pubmed-meshheading:17043635-Female,
pubmed-meshheading:17043635-Humans,
pubmed-meshheading:17043635-Iodine Radioisotopes,
pubmed-meshheading:17043635-Kidney Failure, Chronic,
pubmed-meshheading:17043635-Male,
pubmed-meshheading:17043635-Metabolic Clearance Rate,
pubmed-meshheading:17043635-Middle Aged,
pubmed-meshheading:17043635-Radiopharmaceuticals,
pubmed-meshheading:17043635-Renal Dialysis,
pubmed-meshheading:17043635-Salivary Glands,
pubmed-meshheading:17043635-Stomach,
pubmed-meshheading:17043635-Thyroid Gland,
pubmed-meshheading:17043635-Thyroid Neoplasms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.
|
|
pubmed:affiliation |
Department of Nuclear Medicine, University Hospital Toulouse Rangueil 1, Toulouse, France. courbon.f@chu-toulouse.fr
|
|
pubmed:publicationType |
Journal Article
|
